The table below shows Taysha Gene Therapies, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$40.88M
-$22.02M
-$19.80M
-$20.18M
-$40.94M
-$22.04M
Capital expenditure
$24.00K
$378.00K
$140.00K
$3.90M
$8.43M
$534.00K
Investing cash flow
-$3.02M
-$371.00K
-$140.00K
-$3.90M
-$11.43M
-$534.00K
Dividends paid
-
-
-
TSHA operating cash flow (10-K history)
Taysha Gene Therapies, Inc. reported operating cash flow of -$93.09M for fiscal year 2025. That is down 14.6% from -$81.22M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$30.73M (FY 2020) to -$93.09M. Figures come from the company's audited annual reports as filed with the SEC.